Javier Pinilla, MD, PhD explores evidence on molecular mechanisms leading to resistance in second-generation BTK inhibitors for CLL, providing insights from recently presented data at ASH 2023.
Desai Details Efforts Exploring Treatment Strategies in CLL Post–BTK Inhibitor Progression
Brown Highlights the Rationale for the RAMP-301 Trial in Low-Grade Serous Ovarian Cancer
Genetic Information and Patient Factors Influence BTK Inhibitor Sequencing in Frontline CLL and Beyond
Revisit the OncLive On Air Episodes From February 2024
Pellini Discusses Immunotherapies and Current Limitations of ctDNA in Perioperative NSCLC
Pirtobrutinib Transforms SOC in Later-Line CLL/SLL
Dr Pal Previews ASCO 2024 Data in Renal Cell Carcinoma
Prospective Data Reveal Most Young Survivors of Breast Cancer Could Successfully Give Birth
HPV Vaccinations Associated With Lower Rates of HPV-Caused Cancers in Patients Under 40 Years of Age
AI Virtual Navigation May Reengage Patients to Undergo Missed Colonoscopies